The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Anti-obesity drugs: past, present and future
Open accessAbstract
The ideal anti-obesity drug would produce sustained weight loss with minimal side effects. The mechanisms that regulate energy balance have substantial built-in redundancy, overlap considerably with other physiological functions, and are influenced by social, hedonic and psychological factors that limit the effectiveness of pharmacological interventions. It is therefore unsurprising that anti-obesity drug discovery programmes have been littered with false starts, failures in clinical development, and withdrawals due to adverse effects that were not fully appreciated at the time of launch. Drugs that target pathways in metabolic tissues, such as adipocytes, liver and skeletal muscle, have shown potential in preclinical studies but none has yet reached clinical development. Recent improvements in the understanding of peptidergic signalling of hunger and satiety from the gastrointestinal tract mediated by ghrelin, cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1), and of homeostatic mechanisms related to leptin and its upstream pathways in the hypothalamus, have opened up new possibilities. Although some have now reached clinical development, it is uncertain whether they will meet the strict regulatory hurdles required for licensing of an anti-obesity drug. However, GLP-1 receptor agonists have already succeeded in diabetes treatment and, owing to their attractive body-weight-lowering effects in humans, will perhaps also pave the way for other anti-obesity agents. To succeed in developing drugs that control body weight to the extent seen following surgical intervention, it seems obvious that a new paradigm is needed. In other therapeutic arenas, such as diabetes and hypertension, lower doses of multiple agents targeting different pathways often yield better results than strategies that modify one pathway alone. Some combination approaches using peptides and small molecules have now reached clinical trials, although recent regulatory experience suggests that large challenges lie ahead. In future, this polytherapeutic strategy could possibly rival surgery in terms of efficacy, safety and sustainability of weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management
Hills, A. P., Byrne, N. M., Lindstrom, R., & Hill, J. O. (2013) · Obesity Facts · doi:10.1159/000345030 · Cited by 9,493
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668 · cited 1×
“Bariatric surgery, such as Roux-en-Y bypass or gastric banding, is much more effective in terms of weight loss, comorbidity reduction and enhanced survival (Kral and Naslund, 2007; Sjostrom et al., 2007).”
BackgroundHaslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
Years of Life Lost Due to Obesity
Fontaine, K. R., Redden, D. T., Wang, C., Westfall, A. O., & Allison, D. B. (2003) · JAMA · doi:10.1001/jama.289.2.187 · Cited by 2,495
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Self-citationGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Dansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P., & Schaefer, E. J. (2005) · JAMA · doi:10.1001/jama.293.1.43 · Cited by 1,726
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Cause-Specific Excess Deaths Associated With Underweight, Overweight, and Obesity
Flegal, K. M., Graubard, B. I., Williamson, D. F., & Gail, M. H. (2007) · JAMA · doi:10.1001/jama.298.17.2028 · Cited by 1,542
Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 2×
“Rimonabant, a cannabinoid CB1 receptor antagonist/inverse agonist (see Box 1 for Glossary) developed in the mid-1990s, suppresses appetite and weight gain in experimental animals and, in four major clinical trials, has consistently been found to produce a placebo-subtracted weight loss of 4-5 kg (Despres et al., 2005;…”
BackgroundFreedman, D. S., Khan, L. K., Dietz, W. H., Srinivasan, S. R., & Berenson, G. S. (2001) · Pediatrics · doi:10.1542/peds.108.3.712 · Cited by 1,360
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 2×
“However, cumulative clinical experience has identified some adverse effects, the most serious of which (cardiovascular risk) emerged as a result of a postmarketing clinical trial (James et al., 2010) and led in January 2010 to the suspension of marketing authorisations by the EMA (http://www.”
BackgroundThe Consequences of Childhood Overweight and Obesity
Daniels, S. R. (2006) · The Future of Children · doi:10.1353/foc.2006.0004 · Cited by 934
A self-regulation program for maintenance of weight loss
Wing, R. R., Tate, D. F., Gorin, A. A., Raynor, H. A., & Fava, J. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061883 · Cited by 830
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 2×
“…are treated for diabetes (Wilding and Hardy, 2011), but there is evidence that higher doses of the GLP-1R agonist liraglutide than are necessary for glucose lowering can produce greater weight loss of up to 10 kg in trials of up to 2 years duration (Astrup et al., 2009; Astrup et al., 2011).”
BackgroundScheen, A. J., Finer, N., Hollander, P., Jensen, M. D., & Van Gaal, L. F. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69571-8 · Cited by 736
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Self-citationThe pharmacology of cannabinoid receptors and their ligands: an overview
Pertwee, R. G. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803272 · Cited by 557
LeBlanc, E. S., O'Connor, E., Whitlock, E. P., Patnode, C. D., & Kapka, T. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-7-201110040-00006 · Cited by 400
Rational Design of a Combination Medication for the Treatment of Obesity
Greenway, F. L., Whitehouse, M. J., Guttadauria, M., Anderson, J. W., Atkinson, R. L., Fujioka, K., Gadde, K. M., Gupta, A. K., O'Neil, P., Schumacher, D., et al. (2009) · Obesity · doi:10.1038/oby.2008.461 · Cited by 345
Ravussin, E., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009) · Obesity · doi:10.1038/oby.2009.184 · Cited by 332
Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis
Wasko, M. C. M., Hubert, H. B., Lingala, V. B., Elliott, J. R., Luggen, M. E., Fries, J. F., & Ward, M. M. (2007) · JAMA · doi:10.1001/jama.298.2.187 · Cited by 291
Pancreatic signals controlling food intake; insulin, glucagon and amylin
Woods, S. C., Lutz, T. A., Geary, N., & Langhans, W. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1858 · Cited by 277
Borgström, B. (1988) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(88)90260-3 · Cited by 266
Postpartum Depression: It isn’t just the blues.
Beck, C. T. (2006) · AJN, American Journal of Nursing · doi:10.1097/00000446-200605000-00020 · Cited by 228
Sibutramine: A Review of its Contribution to the Management of Obesity
McNeely, W., & Goa, K. L. (1998) · Drugs · doi:10.2165/00003495-199856060-00019 · Cited by 219
The obesity pipeline: current strategies in the development of anti-obesity drugs
Cooke, D., & Bloom, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 211
Cannabinoids and appetite: food craving and food pleasure
Kirkham, T. C. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782810 · Cited by 189
Kral, J. G., & Näslund, E. B. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0563 · Cited by 179
Long-term weight control study I (weeks 0 to 34)
Weintraub, M., Sundaresan, P. R., Madan, M., Schuster, B., Balder, A., Lasagna, L., & Cox, C. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.69 · Cited by 173
Anorectics on Trial: A Half Century of Federal Regulation of Prescription Appetite Suppressants
Colman, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00013 · Cited by 167
Pharmacological Treatment of the Overweight Patient
Bray, G. A., & Greenway, F. L. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.2 · Cited by 165
Trevaskis, J. L., Coffey, T. S., Cole, R. L., Lei, C., Wittmer, C., Walsh, B., Weyer, C., Koda, J. E., Baron, A., Parkes, D. G., et al. (2008) · Endocrinology · doi:10.1210/en.2008-0770 · Cited by 161
The endocannabinoid system, eating behavior and energy homeostasis: The end or a new beginning?
Bermudez-Silva, F. J., Viveros, M. P., McPartland, J. M., & Rodriguez de Fonseca, F. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.012 · Cited by 160
Pharmacological management of appetite expression in obesity
Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C., & Harrold, J. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.19 · Cited by 157
Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?
Kunos, G., Osei‐Hyiaman, D., Bátkai, S., Sharkey, K. A., & Makriyannis, A. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.001 · Cited by 141
The discovery and status of sibutramine as an anti-obesity drug
Luque, C. A., & Rey, J. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01423-1 · Cited by 128
The utility of animal models to evaluate novel anti‐obesity agents
Vickers, S. P., Jackson, H. C., & Cheetham, S. C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01245.x · Cited by 122
Anti-obesity drugs and neural circuits of feeding
Adan, R. A. H., Vanderschuren, L. J. M. J., & ELAFLEUR, S. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.01.008 · Cited by 120
Broom, J. I., Wilding, J. P. H., Stott, P., Myers, N., & UK Multimorhidity Study Group (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11307.x · Cited by 115
Self-citationMelnikova, I., & Wages, D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2037 · Cited by 110
Vemuri, K. V., Janero, D. R., & Makriyannis, A. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.012 · Cited by 103
Aronne, L. J., Halseth, A. E., Burns, C. M., Miller, S., & Shen, L. Z. (2010) · Obesity · doi:10.1038/oby.2009.478 · Cited by 102
Personalized medicine can pave the way for the safe use of CB1 receptor antagonists
Lazáry, J., Juhász, G., Hunyady, L., & Bagdy, G. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.013 · Cited by 99
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86
Metabolic effects of glucagon in the Wistar rat
SALTER, J. M. (1960) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/8.5.535 · Cited by 85 · cited 2×
“Glucagon is a pancreatic hormone with well-established thermogenic, anorectic and weight loss effects in animals (Salter, 1960; Woods et al., 2006), whereas GLP-1R agonism (e.g. with exenatide) is known to improve glycaemic control and weight loss in humans with type 2 diabetes (e.g. Hanssen et…”
BackgroundKennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 77
New central targets for the treatment of obesity
Sargent, B. J., & Moore, N. A. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03550.x · Cited by 76
Obesity treatment: novel peripheral targets
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03522.x · Cited by 73
The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior
Randall, P. A., Vemuri, K. V., Segovia, K. N., Torres, E. F., Hosmer, S., Nunes, E. J., Santerre, J. L., Makriyannis, A., & Salamone, J. D. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.021 · Cited by 70
Rodgers, R. J., Holch, P., & Tallett, A. J. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.001 · Cited by 68
Self-citationDaniels, J. (2006) · AJN American Journal of Nursing · doi:10.1097/00000446-200601000-00028 · Cited by 65
Cluny, N. L., Chambers, A. P., Vemuri, K. V., Wood, J. T., Eller, L. K., Freni, C., Reimer, R. A., Makriyannis, A., & Sharkey, K. A. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.10.013 · Cited by 51
Ward, S. J., Lefever, T. W., Jackson, C., Tallarida, R. J., & Walker, E. A. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131771 · Cited by 47
Roth, J. D., Trevaskis, J. L., Wilson, J., Lei, C., Athanacio, J., Mack, C. M., Kesty, N. C., Coffey, T. S., Weyer, C., & Parkes, D. G. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.91 · Cited by 42
“Weighing in” on synergy: Preclinical research on neurohormonal anti-obesity combinations
Roth, J. D., Trevaskis, J. L., Turek, V. F., & Parkes, D. G. (2010) · Brain Research · doi:10.1016/j.brainres.2010.01.027 · Cited by 37
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Hansen, K. B., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02086.x · Cited by 37
Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.02.009 · Cited by 33
Self-citationLockie, S. H., Czyzyk, T. A., Chaudhary, N., Pérez–Tilve, D., Woods, S. C., Oldfield, B. J., Statnick, M. A., & Tschöp, M. H. (2011) · Endocrinology · doi:10.1210/en.2011-1220 · Cited by 24
Self-citationAdditive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition
Orío, L., Crespo, I., López‐Moreno, J. A., Reyes‐Cabello, C., de Fonseca, F. R., & de Heras, R. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.007 · Cited by 24
Glucagon-like peptide-1 analogues for type 2 diabetes
Wilding, J. P. H., & Hardy, K. J. (2011) · BMJ · doi:10.1136/bmj.d410 · Cited by 23
Self-citationAstrup, A., Carraro, R., Finer, N., Harper, A., Kunešová, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., Rössner, S., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.203 · Cited by 9
Clinical Investigations of Antiobesity Drugs
Wilding, J. P. H. (2007) · Elsevier eBooks · doi:10.1016/b978-012370633-1/50014-1 · Cited by 8
Self-citationPreclinical Developments in Antiobesity Drugs
Vickers, S. P., & Cheetham, S. C. (2007) · Elsevier eBooks · doi:10.1016/b978-012370633-1/50013-x · Cited by 7
Cited by
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Self-citationEmdin, C. A., Khera, A. V., Natarajan, P., Klarin, D., Zekavat, S. M., Hsiao, A. J., & Kathiresan, S. (2017) · JAMA · doi:10.1001/jama.2016.21042 · Cited by 378
Serotonin controlling feeding and satiety
Voigt, J.-P., & Fink, H. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.08.065 · Cited by 312
Zaykov, A. N., Mayer, J. P., & DiMarchi, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.36 · Cited by 287
Adipokines – removing road blocks to obesity and diabetes therapy
Blüher, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.005 · Cited by 273
Metadata
- Authors
- Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. H.
- Venue
- Disease Models & Mechanisms
- Publisher
- The Company of Biologists
- Published
- 2012-09-01
- Volume
- 5
- Issue
- 5
- Pages
- 621-626
- ISSN
- 1754-8403 (ISSN-L)
- 1754-8411
- OpenAlex
- W2160235960
- Cited by
- 430
- References
- 73
- FWCI
- 21.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.